Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IGBA Backs Global Coronavirus Initiative

'Landmark' Collaboration Project Launched By WHO

Executive Summary

The IGBA has lent its backing to the Access to COVID-19 Tools (ACT) Accelerator initiative launched by the WHO that is aimed at speeding the development and production of – as well as access to – essential health technologies for addressing the coronavirus pandemic.

You may also be interested in...



Bill & Melinda Gates Foundation Commits $120m For Molnupiravir In Lower-Income Countries

The Bill & Melinda Gates Foundation has extended a financial commitment of up to $120m to secure a dedicated, low-cost supply of generic molnupiravir to lower-income countries. The Gates Foundation is looking to “significantly reduce the time it takes for a new drug to reach low-income countries after it becomes available in high-income markets.”

Medicines Patent Pool Prepared To Step In On Vaccines

The Medicines Patent Pool says it is ready to step in to assist with voluntary licensing and technology transfer around COVID-19 vaccines, following US support for an IP waiver.

IPA’s Jain Predicts 3-4 Weeks To Meet Indian Shortages

Speaking exclusively to Generics Bulletin, Indian Pharmaceutical Alliance secretary general Sudarshan Jain says that India’s needs for COVID drugs like favipiravir, remdesivir and tocilizumab will be met “in the near future.” Current IGBA chair Jain also talks about global collaboration by governments and donors for equal vaccine distribution through the Access to COVID-19 Tools Accelerator.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB149847

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel